Physician profile
Clifton A Sheets
NPI 1831287945
$3,807.17
in general payments reported to CMS, 2019-2025
26 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what 96% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2022: $381 · 2023: $1,078 · 2024: $1,046 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.72 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $555.25 | 2023-2025 | |
| Lilly USA, LLC | $393.95 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $385.95 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $383.19 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $334.59 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $148.94 | 2024 | Veozah |
| Exact Sciences Corporation | $96.21 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $70.99 | 2022-2023 | Trintellix |
| Antares Pharma, INC. | $70.54 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Axsome Therapeutics, INC. | $67.33 | 2024-2025 | Auvelity |
| Boston Scientific Corporation | $64.37 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.26 | 2022-2024 | Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $58.95 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.65 | 2025 | Caplyta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $56.89 | 2019 | |
| Dexcom, INC. | $56.59 | 2023-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $55.15 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $35.47 | 2022 | |
| Azurity Pharmaceuticals, INC. | $23.44 | 2025 | Azmiro |
| Convatec INC. | $22.04 | 2025 | |
| Avion Pharmaceuticals | $20.78 | 2022 | |
| Therapeuticsmd, INC. | $20.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.67 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.38 | 2024 | Ycanth |
| Teva Pharmaceuticals USA, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifton Sheets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.